Intra-Cellular Therapies (ITCI) Tops Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update
March 2, 2020 7:30 AM ESTNEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year ending December 31, 2019, and provided a corporate update.
We are very excited about the recent FDA approval of CAPLYTA (lumateperone) for the treatment of schizophrenia and we are fully prepared for our planned commercial launch later this month, said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. We have also continued to advance our... More
